$OncoSec Medical Incorporated (ONCS)$ SITC late breaking P717: Initial report of intratumoral tavokinogene telseplasmid with pembrolizumab in advanced melanoma: an approach designed to convert PD-1 antibody progressors into responders. (NCT 03132675)